These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 23375823

  • 1. Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: an analysis with pinaverium bromide 100mg plus simethicone 300mg po bid.
    López-Alvarenga JC, Sobrino-Cossío S, Remes-Troche JM, Chiu-Ugalde J, Vargas-Romero JA, Schmulson M.
    Rev Gastroenterol Mex; 2013; 78(1):21-7. PubMed ID: 23375823
    [Abstract] [Full Text] [Related]

  • 2. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome.
    Urgesi R, Casale C, Pistelli R, Rapaccini GL, de Vitis I.
    Eur Rev Med Pharmacol Sci; 2014; 18(9):1344-53. PubMed ID: 24867512
    [Abstract] [Full Text] [Related]

  • 3. Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies.
    Basseri RJ, Kunkel D, Low K, Conklin JL, Pimentel M.
    J Clin Gastroenterol; 2011 Oct; 45(9):790-3. PubMed ID: 21301356
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial.
    Schmulson MJ, Chiu-Ugalde J, Sáez-Ríos A, López-Colombo A, Mateos-Pérez GJ, Remes-Troche JM, Sobrino-Cossio S, Soto-Pérez JC, Tamayo de la Cuesta JL, Teramoto-Matsubara OT, López-Alvarenga JC.
    J Clin Gastroenterol; 2020 Apr; 54(4):e30-e39. PubMed ID: 31385885
    [Abstract] [Full Text] [Related]

  • 5. Pinaverium Reduces Symptoms of Irritable Bowel Syndrome in a Multicenter, Randomized, Controlled Trial.
    Zheng L, Lai Y, Lu W, Li B, Fan H, Yan Z, Gong C, Wan X, Wu J, Huang D, Wang Y, Mei Y, Li Z, Jiang Z, Liu X, Ye J, Yang Y, Huang H, Xiao J.
    Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1285-1292.e1. PubMed ID: 25632806
    [Abstract] [Full Text] [Related]

  • 6. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS.
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [Abstract] [Full Text] [Related]

  • 7. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM, Shiff SJ, Quigley EM.
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [Abstract] [Full Text] [Related]

  • 8. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):435-44. PubMed ID: 15709995
    [Abstract] [Full Text] [Related]

  • 9. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification.
    Engsbro AL, Simren M, Bytzer P.
    Aliment Pharmacol Ther; 2012 Feb 15; 35(3):350-9. PubMed ID: 22176384
    [Abstract] [Full Text] [Related]

  • 10. Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III.
    Ersryd A, Posserud I, Abrahamsson H, Simrén M.
    Aliment Pharmacol Ther; 2007 Sep 15; 26(6):953-61. PubMed ID: 17767480
    [Abstract] [Full Text] [Related]

  • 11. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P.
    Gut; 2005 Dec 15; 54(12):1707-13. PubMed ID: 16020489
    [Abstract] [Full Text] [Related]

  • 12. Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study.
    Yao X, Yang YS, Cui LH, Zhao KB, Zhang ZH, Peng LH, Guo X, Sun G, Shang J, Wang WF, Feng J, Huang Q.
    J Gastroenterol Hepatol; 2012 Apr 15; 27(4):760-5. PubMed ID: 21929652
    [Abstract] [Full Text] [Related]

  • 13. Development of the Diary for Irritable Bowel Syndrome Symptoms to Assess Treatment Benefit in Clinical Trials: Foundational Qualitative Research.
    Fehnel SE, Ervin CM, Carson RT, Rigoni G, Lackner JM, Coons SJ, Critical Path Institute Patient-Reported Outcome Consortium’s Irritable Bowel Syndrome Working Group.
    Value Health; 2017 Apr 15; 20(4):618-626. PubMed ID: 28408004
    [Abstract] [Full Text] [Related]

  • 14. [A comparison between Rome III and Rome II criteria in diagnosing irritable bowel syndrome].
    Wang AJ, Liao XH, Hu PJ, Liu SC, Xiong LS, Chen MH.
    Zhonghua Nei Ke Za Zhi; 2007 Aug 15; 46(8):644-7. PubMed ID: 17967234
    [Abstract] [Full Text] [Related]

  • 15. Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study).
    Garrigues V, Mearin F, Badía X, Balboa A, Benavent J, Caballero A, Domínguez E, Díaz-Rubio M, Roset M, Figueras M, Cucala M, RITMO GROUP.
    Aliment Pharmacol Ther; 2007 Feb 01; 25(3):323-32. PubMed ID: 17217445
    [Abstract] [Full Text] [Related]

  • 16. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study.
    Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Delestrain MC.
    Aliment Pharmacol Ther; 2010 Mar 01; 31(6):615-24. PubMed ID: 20003095
    [Abstract] [Full Text] [Related]

  • 17. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial.
    Pace F, Maurano A, Ciacci C, Savarino V, Attili A, Iaquinto G, Magni E, Porro GB.
    Eur Rev Med Pharmacol Sci; 2010 Mar 01; 14(3):155-62. PubMed ID: 20391952
    [Abstract] [Full Text] [Related]

  • 18. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome.
    Tillisch K, Labus JS, Naliboff BD, Bolus R, Shetzline M, Mayer EA, Chang L.
    Am J Gastroenterol; 2005 Apr 01; 100(4):896-904. PubMed ID: 15784038
    [Abstract] [Full Text] [Related]

  • 19. Subtypes of irritable bowel syndrome in children: prevalence at diagnosis and at follow-up.
    Giannetti E, de'Angelis G, Turco R, Campanozzi A, Pensabene L, Salvatore S, de Seta F, Staiano A.
    J Pediatr; 2014 May 01; 164(5):1099-1103.e1. PubMed ID: 24485818
    [Abstract] [Full Text] [Related]

  • 20. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group.
    Zhonghua Nei Ke Za Zhi; 2003 Feb 01; 42(2):88-90. PubMed ID: 12783702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.